Home » Authors » James Etheridge

Articles by James Etheridge

Neurotech Acquires Exclusive License From Amgen For CNTF

Jan. 16, 2002

By James Etheridge

Neurotech Acquires Exclusive License From Amgen For CNTF

Jan. 16, 2002

By James Etheridge

French Parliament Could Vote To Allow Therapeutic Cloning

Jan. 16, 2002

By James Etheridge

ExonHit Partners With IDEC To Develop Antibody Therapeutics

Jan. 9, 2002

By James Etheridge

PARIS - ExonHit Therapeutics SA and IDEC Pharmaceuticals Corp. signed a collaboration and research agreement aimed at discovering new antigen targets for antibody therapy, with a particular focus on prostate carcinoma.

ExonHit Partners With IDEC To Develop Antibody Therapeutics

Jan. 9, 2002

By James Etheridge

PARIS - ExonHit Therapeutics SA and IDEC Pharmaceuticals Corp. signed a collaboration and research agreement aimed at discovering new antigen targets for antibody therapy, with a particular focus on prostate carcinoma.

Crucell Unveils AdVac, Its New Genetic Vaccination Technology

June 6, 2001

By James Etheridge

Crucell Unveils AdVac, Its New Genetic Vaccination Technology

June 6, 2001

By James Etheridge

Transgene Financing Nets $54M; BioMérieux Stake Reaches 70%

May 30, 2001

By James Etheridge

Hybrigenics, Institut Curie Create Joint Cancer Research Facility

May 30, 2001

By James Etheridge

Neurotech Raises $30M Privately To Fund Work In Cell Therapies

May 30, 2001

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...